REGENCOR - Key Persons

David Greenwood

Job Titles:
  • Corporate Finance / Investment
Investment banker and Public Biotech CFO for 30 years. Public Biotech CEO and Executive Chairman for 5 years. Board Director for seven life sciences companies.

Dr. Albert Chin

Job Titles:
  • EpicaPatch Delivery Catheter Design

Jane Lebkowski

Job Titles:
  • Advisor

Mark Mercola

Job Titles:
  • Director

Nabil Dib

Job Titles:
  • Clinical Head MyoBead Development
  • Director of Cardiovascular Research at Dignity Health
Dr. Dib is the Director of Cardiovascular Research at Dignity Health in Phoenix, Arizona, and is the Founder and President of the International Society for Cardiovascular Translational Research. A Harvard-trained cardiologist, he is internationally recognized as an interventional cardiologist and pioneer in coronary infusion technologies. Dr. Dib has participated as an investigator in over 65 clinical trials of cardiovascular devices, and cell and gene therapies for cardiovascular disease. He is the inventor of the ND Infusion Catheter, a widely used FDA cleared medical device for the introduction of cells, biologicals and pharmaceuticals directly into coronary arteries.

Pilar Ruiz-Lozano

Job Titles:
  • Chief Scientific Officer
  • Member of the LEADERSHIP Team
As a member of the Faculty at Stanford School of Medicine and the Sanford-Burnham-Prebys Institute, she pioneered the development of tissue engineering and epicardial biology to treat heart disease. She led the discovery of the cardiac regenerative properties of recombinant human FSTL1 and the development of delivery modalities that are now licensed by Regencor, Inc.

Sigalit Caron

Job Titles:
  • Regulatory Affairs Quality Control / Expert in Regulatory Affairs, Clinical Research and Business Development Focused on Cardiovascular Medicine
Expert in regulatory affairs, clinical research and business development focused on cardiovascular medicine.

Skylar David Huang

Job Titles:
  • NIH Grants Administration Accounting

Thomas Okarma - CEO, Chairman, President

Job Titles:
  • CEO
  • Chairman
  • Member of the LEADERSHIP Team
  • President
Dr. Okarma brings over 30 years' experience as CEO of three publicly traded companies, including Geron Corporation, where he was responsible for the world's first FDA authorized IND for human embryonic stem cells, a milestone in biotechnology. While at Geron, he also managed the development of Imetelstat, the world's only telomerase inhibitor drug currently in advanced clinical testing for hematologic malignancies. Dr. Okarma was also a Senior Vice President of Rhone Poulenc Rorer, following their acquisition of his first company, Applied Immune Sciences. Under Dr. Okarma's leadership, Regencor has attracted and retained highly trained and experienced employees, consultants, and CROs/CMOs.